Grace Therapeutics (GRCE) Cash from Operations (2019 - 2026)
Grace Therapeutics (GRCE) posted Cash from Operations of 1695000.0 for Q1 2026, up 23.99% sequentially from 2230000.0 in Q4 2025, and up 42.62% YoY from 1188471.4 in Q1 2025.
Grace Therapeutics (GRCE) Cash from Operations (2019 - 2026) Analysis & Trends
Grace Therapeutics has reported Cash from Operations for 8 years, with the latest figure at 1695000.0 in Q1 2026.
- Quarterly Cash from Operations rose 42.62% year-over-year to 1695000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8869000.0 (up 40.49% YoY) and the FY2026 annual result came in at 8869000.0, up 40.49% from the prior year.
- Cash from Operations improved to 1695000.0 in Q1 2026 per GRCE's latest filing, from 2230000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 1695000.0 in Q1 2026 and troughed at 6240000.0 in Q2 2023.
- A 5-year average of 3244941.18 and a median of 3145000.0 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations tumbled 117.49% in 2024, then jumped 49.92% in 2025.
- Over 5 years, Cash from Operations stood at 3722000.0 in 2022, then jumped by 49.17% to 1892000.0 in 2023, then sank by 117.49% to 4115000.0 in 2024, then soared by 45.81% to 2230000.0 in 2025, then climbed by 23.99% to 1695000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 1695000.0, 2230000.0, and 3143000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 326.72 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -88.83 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 728.46 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.27 Mn |
| 10 | Grace Therapeutics | 37.04 Mn | 37.04 Mn | - | -3.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.22 Mn |
| Jun 30, 2026 | -3.22 Mn |
| Mar 31, 2026 | -1.70 Mn |
| Mar 31, 2026 | -1.70 Mn |
| Dec 31, 2025 | -2.23 Mn |
| Dec 31, 2025 | -2.23 Mn |
| Sep 30, 2025 | -3.14 Mn |
| Sep 30, 2025 | -3.14 Mn |
| Jun 30, 2025 | -1.80 Mn |
| Jun 30, 2025 | -1.80 Mn |
| Mar 31, 2025 | -2.95 Mn |
| Mar 31, 2025 | -2.95 Mn |
| Dec 31, 2024 | -4.12 Mn |
| Dec 31, 2024 | -4.12 Mn |
| Sep 30, 2024 | -4.24 Mn |
| Sep 30, 2024 | -4.24 Mn |
| Jun 30, 2024 | -3.60 Mn |
| Jun 30, 2024 | -3.60 Mn |
| Mar 31, 2024 | -2.09 Mn |
| Mar 31, 2024 | -2.09 Mn |